Compare Boston Scientific Corporation (BSX) vs First Trust NASDAQ Cybersecurity ETF (CIBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs First Trust NASDAQ Cybersecurity ETF — how do they compare? Boston Scientific Corporation trades at $42.65 (market cap $66.37B), while First Trust NASDAQ Cybersecurity ETF trades at $95.49. The key difference: First Trust NASDAQ Cybersecurity ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | CIBR | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | — |
52-Week High | $108.14 | $94.73 |
52-Week Low | $42.63 | $60.74 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
CIBR trades at $91.84, down 0.04% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The ETF has demonstrated strong performance, outperforming the S&P 500 by a three-to-one margin year-to-date, driven by robust cybersecurity spending trends. A dividend of $0.07 is scheduled for June 30, 2026. Recent news highlights institutional accumulation and positive momentum in the cybersecurity sector.
The outlook for CIBR is supported by growing global cybersecurity expenditures, projected to exceed $300 billion in 2026, and AI-driven demand. Risks include sector volatility and concentrated tech exposure. Analyst sentiment is positive, with recent upgrades citing reasonable valuation and secular growth, though investors should weigh high institutional interest against market cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About First Trust NASDAQ Cybersecurity ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.
Read more on CIBR →
